BRAF and neoplasm: Hence, the conclusion from this study was that vemurafenib restores RAI uptake and efficacy in a subset of BRAF mutant RAIR patients, probably by upregulating thyroid-specific gene expression via MAPK pathway inhibition, and that higher baseline thyroglobulin values among responders suggest that tumor differentiation status may be a predictor of vemurafenib benefit [86].